Seagen
Seagen is a U.S. oncology biotechnology company known for pioneering antibody-drug conjugates and developing cancer medicines including Adcetris, Padcev, and Tivdak.
Last updated October 18, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Seagen was an American biotechnology and oncology company founded in 1997 as Seattle Genetics by Henry Perry Fell Jr. and Clay Siegall. Based in Bothell, Washington, the company built its identity around the discovery, development, and commercialization of targeted cancer medicines, especially antibody-drug conjugates, or ADCs. In an ADC, a monoclonal antibody is linked to a cytotoxic payload so that the antibody can recognize a biological target associated with cancer cells and transport the payload into or near the tumor. Seagen’s platform used proprietary linker and payload technologies, including monomethyl auristatin E, or MMAE, to pursue more selective delivery than conventional chemotherapy. The company’s most important early achievement was brentuximab vedotin, marketed as Adcetris. The medicine targets CD30, a protein expressed on several hematologic malignancies, and became a central treatment for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Seagen developed the product with Takeda Oncology, retaining commercialization rights in the United States and Canada while Takeda handled many markets outside North America. Adcetris helped transform Seattle Genetics from a development-stage biotechnology company into a commercial oncology business and supported additional clinical studies in earlier treatment settings and other CD30-positive cancers. Seagen subsequently broadened its portfolio through internal research, licensing, and strategic partnerships. Its ADC collaborations involved companies including Takeda, Genmab, Astellas, Pfizer, Genentech, Bayer, GlaxoSmithKline, AbbVie, Daiichi Sankyo, Oxford BioTherapeutics, and others. Several programs advanced through clinical development, although not every investigational candidate reached commercialization. The company also acquired Cascadian Therapeutics in 2018, adding tucatinib, which later became the basis of Tukysa, a targeted medicine used in certain HER2-positive cancers. The company’s later commercial portfolio expanded beyond Adcetris. Enfortumab vedotin, developed with Astellas Pharma and marketed as Padcev, became an important treatment for urothelial cancer and was studied in additional solid tumors. Tisotumab vedotin, developed with Genmab and marketed as Tivdak, targeted tissue factor and was approved for certain patients with recurrent or metastatic cervical cancer. Tukysa added an oral small-molecule therapy to a portfolio otherwise strongly associated with ADCs. Together, these products gave Seagen exposure to hematologic cancers, bladder and other urothelial cancers, cervical cancer, breast cancer, and additional solid-tumor research areas. Seattle Genetics changed its corporate name to Seagen in 2020, reflecting the company’s expansion beyond its original Seattle Genetics identity and its increasingly international commercial presence. In the same period, Merck & Co. made a $1 billion equity investment in Seagen and entered a collaboration involving ladiratuzumab vedotin, although Merck acquisition discussions reported in 2022 did not result in a transaction. In November 2022, Seagen appointed David R. Epstein as chief executive officer and a director, succeeding long-serving leadership during a period of strategic transition. In March 2023, Pfizer agreed to acquire Seagen for an enterprise value of approximately $43 billion, or $229 in cash per share. Pfizer completed the transaction on December 14, 2023. The acquisition ended Seagen’s existence as an independent public company but brought its ADC platform, oncology portfolio, research pipeline, and commercial infrastructure into Pfizer’s oncology organization. Seagen therefore remains significant as a technology and product-origin brand within Pfizer, even though its former Nasdaq-listed corporate structure no longer operates independently.
History
Seagen originated in 1997 as Seattle Genetics, founded by Henry Perry Fell Jr. and Clay Siegall in the Seattle-area biotechnology community. The founders established the company to develop antibody-based cancer therapies and to create a platform capable of linking tumor-targeting antibodies with potent cell-killing agents. This approach later became known as antibody-drug conjugate technology and formed the core of the company’s scientific and commercial identity. The company’s early development was built around research partnerships and a pipeline of experimental antibody therapeutics. During the late 2000s, Seattle Genetics advanced brentuximab vedotin, initially known as SGN-35, through pivotal studies in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. The program demonstrated the potential of using an antibody to recognize CD30-positive malignant cells while delivering the auristatin payload MMAE. In parallel, the company tested other ADCs and antibody programs, terminated or restructured selected collaborations, and expanded relationships with major pharmaceutical companies including Genentech, Bayer, GlaxoSmithKline, Pfizer, MedImmune, Genmab, Agensys, and Takeda Oncology. A key strategic decision during this period was to develop commercial capabilities rather than remain solely a licensing and research organization. As Adcetris approached the market, Seattle Genetics built a commercial team for the United States and Canada and partnered with Takeda for many markets outside North America. This arrangement allowed the company to retain a direct commercial presence in its home market while using Takeda’s international infrastructure. The company also continued to invest in broad clinical development, studying Adcetris in earlier lines of therapy, additional lymphoma settings, and other CD30-expressing malignancies. In August 2011, the FDA granted accelerated approval to Adcetris for relapsed Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Health Canada approved the medicine in 2013 for relapsed or refractory Hodgkin lymphoma. Adcetris became the company’s defining product and provided a recurring commercial base for continued oncology research. Seattle Genetics continued to initiate trials involving Adcetris combinations, post-transplant treatment, untreated advanced Hodgkin lymphoma, cutaneous T-cell lymphoma, diffuse large B-cell lymphoma, and other potential indications. The company expanded its scientific portfolio through collaborations and internal programs. Investigational candidates included SGN-75, SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-5ME, and other ADCs directed at targets associated with hematologic or solid tumors. Some programs were discontinued or failed to become commercial products, illustrating the high attrition rate typical of oncology drug development. Nevertheless, the company’s proprietary MMAE-based technology and linker systems attracted repeated alliances with large pharmaceutical companies. In January 2018, Seattle Genetics announced the acquisition of Cascadian Therapeutics for approximately $614 million. The transaction added tucatinib, a small-molecule HER2-directed therapy, and broadened the company beyond its primary ADC focus. Tucatinib was later commercialized as Tukysa for certain HER2-positive breast and colorectal cancer settings. In 2020, the company changed its corporate name to Seagen Inc. The renaming reflected a broader global identity and a portfolio that included multiple oncology modalities and geographic markets. Also in 2020, Merck & Co. purchased approximately $1 billion of Seagen stock and entered a collaboration related to ladiratuzumab vedotin. The relationship underscored Seagen’s value as an ADC technology company and a source of oncology innovation. Reports in 2022 described possible Merck acquisition discussions, but no deal followed. In November 2022, Seagen appointed David R. Epstein as chief executive officer and director. Pfizer announced its definitive agreement to acquire Seagen in March 2023. Pfizer offered $229 per share in cash, corresponding to an enterprise value of approximately $43 billion. The transaction was completed on December 14, 2023, after required regulatory clearances. Seagen consequently ceased to be an independent Nasdaq-listed corporation and became part of Pfizer. Its products, development programs, and ADC capabilities were incorporated into Pfizer’s oncology strategy. Seagen’s historical importance therefore rests both in its medicines and in its role in advancing ADCs from a specialized biotechnology concept into a commercially significant cancer-treatment platform.
- 2023
Pfizer announces acquisition agreement
[6]Pfizer agreed to acquire Seagen for approximately $43 billion in enterprise value.
- 2023
Pfizer completes acquisition
[2]Pfizer completed the acquisition on December 14, 2023, ending Seagen’s status as an independent public company.
- 2022
David R. Epstein becomes chief executive officer
[1]Seagen appointed David R. Epstein as chief executive officer and director.
- 2020
Corporate name changes to Seagen
[1]Seattle Genetics adopted Seagen Inc. as its corporate name.
- 2020
Merck equity investment and collaboration
[1]Merck invested approximately $1 billion in Seagen common stock and entered an oncology collaboration involving ladiratuzumab vedotin.
- 2018
Cascadian Therapeutics acquisition announced
[1]Seattle Genetics agreed to acquire Cascadian Therapeutics, adding the tucatinib program to its oncology portfolio.
- 2013
Health Canada approves Adcetris
[1]Health Canada approved Adcetris for relapsed or refractory Hodgkin lymphoma.
- 2011
Adcetris receives accelerated FDA approval
[1]Brentuximab vedotin, marketed as Adcetris, received accelerated U.S. approval for relapsed Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.
- 2009
Brentuximab vedotin enters pivotal development
[1]Seattle Genetics initiated pivotal and supporting studies of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.
- 2001
Initial public offering
[1]The company completed an initial public offering and began trading on Nasdaq under the symbol SGEN.
Products and positioning
Precision oncology biotechnology centered on antibody-drug conjugates, targeted delivery of cytotoxic payloads, and therapies for hematologic malignancies and solid tumors.
Antibody-drug conjugate · 2011
Adcetris
Adcetris is the brand name for brentuximab vedotin, an antibody-drug conjugate directed at CD30. The antibody component binds CD30-expressing malignant cells and delivers the MMAE cytotoxic payload through a specialized linker. It became Seagen’s foundational commercial product after receiving accelerated FDA approval in 2011 for relapsed Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. The company and its partners subsequently pursued additional indications, treatment settings, and combinations in lymphoma and other CD30-positive diseases.
Antibody-drug conjugate · 2019
Padcev
Padcev is the brand name for enfortumab vedotin, an antibody-drug conjugate directed against Nectin-4, a target expressed in several solid tumors. Seagen developed the product in partnership with Astellas Pharma. Its principal commercial role has been in urothelial cancer, including advanced bladder cancer settings, with additional clinical development in other solid tumors. Padcev extended Seagen’s ADC expertise from hematologic malignancies into a major solid-tumor category.
Antibody-drug conjugate · 2021
Tivdak
Tivdak is the brand name for tisotumab vedotin, an antibody-drug conjugate directed at tissue factor. Developed with Genmab, the medicine was designed for cancer treatment by combining antibody targeting with a cytotoxic payload. It became associated with treatment of recurrent or metastatic cervical cancer after prior systemic therapy and represented Seagen’s expansion into gynecologic oncology. Its development also demonstrated the company’s strategy of applying ADC technology to targets outside the CD30 and Nectin-4 programs.
Small-molecule kinase inhibitor · 2020
Tukysa
Tukysa is the brand name for tucatinib, an orally administered HER2-directed small-molecule tyrosine kinase inhibitor obtained through Seagen’s acquisition of Cascadian Therapeutics. Unlike Seagen’s principal ADC products, Tukysa is a targeted small-molecule therapy. It broadened the company’s commercial portfolio into HER2-positive breast and colorectal cancer treatment and provided a complementary modality for precision oncology.
Investigational antibody-drug conjugate
SGN-75
SGN-75, also known as vorsetuzumab mafodotin, was an investigational ADC comprising a humanized monoclonal antibody linked to the MMAF payload through a non-cleavable linker. The program was evaluated in relapsed or refractory renal-cell carcinoma and non-Hodgkin lymphoma research. It illustrates Seagen’s earlier efforts to develop multiple auristatin-based ADCs beyond brentuximab vedotin.
Investigational antibody-drug conjugate
ASG-5ME
ASG-5ME was an investigational ADC directed at SLC44A4 and studied in solid tumors including pancreatic, prostate, and gastric cancers. The program was developed through collaboration and reflected Seagen’s attempt to extend its ADC platform into targets and disease areas outside hematologic oncology.
Antibody-drug conjugate
Enfortumab vedotin
Enfortumab vedotin was Seagen’s development name for the ADC later marketed as Padcev. It targets Nectin-4 and was developed in a partnership with Astellas Pharma for urothelial and other solid tumors.
Antibody-drug conjugate
Tisotumab vedotin
Tisotumab vedotin was the development name for the ADC later marketed as Tivdak. Developed with Genmab, it targets tissue factor and became a commercial treatment for certain patients with recurrent or metastatic cervical cancer.
Investigational antibody-drug conjugate
SGN-LIV1A
SGN-LIV1A was an investigational ADC targeting LIV-1, a protein associated with certain breast cancers and other malignancies. Seagen initiated clinical testing in metastatic breast cancer, but the program did not become one of the company’s marketed products.
Investigational antibody-drug conjugate
SGN-CD19A
SGN-CD19A was an investigational ADC aimed at CD19-positive hematologic malignancies. It formed part of Seagen’s research effort to apply its payload and linker technology to additional immune-cell and blood-cancer targets.
Controversies
2019
Daiichi Sankyo files declaratory judgment action against Seattle Genetics
Daiichi Sankyo filed a declaratory judgment action in the District Court of Delaware in a dispute with Seattle Genetics over rights to linker technology used in antibody-drug conjugates, including DS-8201. Seattle Genetics said Daiichi's filing circumvented the dispute-resolution process in their former agreement; both parties disputed the other's claims to the technology.
Brand decisions
2024
Cancel planned Everett manufacturing facilityStrategyBackground
After acquiring Seagen, Pfizer reassessed its manufacturing and investment plans in Washington State amid broader portfolio and capacity decisions.
Action taken
Pfizer abandoned plans for a large manufacturing facility in Everett, Washington, that had been expected to support the combined organization.
Aftermath
The decision reduced the expected local manufacturing investment associated with the post-acquisition Seagen expansion.
2023
Accept Pfizer acquisition offerM&ABackground
Pfizer sought to strengthen its oncology business and gain access to Seagen’s ADC platform, marketed medicines, development pipeline, and commercial capabilities.
Action taken
Seagen agreed to be acquired by Pfizer for $229 in cash per share, representing an announced enterprise value of approximately $43 billion.
Aftermath
Pfizer completed the acquisition on December 14, 2023. Seagen ceased to be an independent public company and became part of Pfizer’s oncology organization.
Enterprise value. Approximately $43 billion (Announced March 2023; completed December 14, 2023)
2020
Adopt the Seagen corporate nameStrategyBackground
The company had expanded beyond its original Seattle Genetics identity through international operations, multiple therapeutic programs, and a broader oncology portfolio.
Action taken
Seattle Genetics changed its corporate name to Seagen Inc.
Aftermath
The Seagen name became the company’s principal corporate and investor identity until Pfizer acquired the business in 2023.
2020
Enter a major equity and development collaboration with MerckStrategyBackground
Merck sought access to Seagen’s oncology platform and ADC capabilities, while Seagen gained capital and a large-pharmaceutical development partner.
Action taken
Merck agreed to purchase approximately $1 billion of Seagen common stock and to collaborate on ladiratuzumab vedotin and related oncology development.
Aftermath
The transaction reinforced Seagen’s position as a strategically important ADC company, although reported acquisition discussions between the parties in 2022 did not produce a purchase agreement.
Equity investment. Approximately $1 billion (Announced September 2020)
2018
Acquire Cascadian TherapeuticsM&ABackground
Seagen sought to broaden its oncology portfolio beyond its established ADC programs and add a targeted therapy with potential in HER2-positive cancers.
Action taken
The company agreed to acquire Cascadian Therapeutics for approximately $614 million.
Aftermath
The acquisition added tucatinib, which was later commercialized as Tukysa and expanded Seagen into oral targeted oncology treatment.
Transaction value. Approximately $614 million (Announced January 2018)
2009
Build direct commercial capabilities in North AmericaStrategyBackground
As Adcetris moved toward potential commercialization, Seattle Genetics determined that it needed internal commercial expertise rather than relying entirely on external licensing or marketing partners.
Action taken
The company built a commercial organization for the United States and Canada while arranging a collaboration with Takeda Oncology for commercialization in many other markets.
Aftermath
The approach gave Seagen direct control in its principal home market and helped establish a commercial foundation for its later portfolio expansion.
Recent events
Pfizer and Seagen receive required approvals for acquisition[8]
Reported:
Pfizer and Seagen received all required regulatory approvals to complete Pfizer's pending acquisition of Seagen. Pfizer said it expected the transaction to close on December 14, subject to customary closing conditions.
Pieris and Seagen amended their collaboration and entered a clinical trial collaboration[9]
Reported:
Pieris and Seagen announced a clinical trial collaboration to evaluate combining Pieris' cinrebafusp alfa with Seagen's TUKYSA in a planned phase 2 study. They also amended their existing immuno-oncology collaboration, changing Pieris' co-development and co-commercialization option for one program to a US co-promotion option with increased royalties if exercised.
Seagen invested $13 million in Pieris[9]
Reported:
Seagen made a $13 million equity investment in Pieris through a private placement, purchasing 3,706,174 newly issued shares at $3.51 per share.
Daiichi Sankyo files declaratory judgment action against Seattle Genetics[7]
Reported:
Daiichi Sankyo filed a declaratory judgment action in the District Court of Delaware in a dispute with Seattle Genetics over rights to linker technology used in antibody-drug conjugates, including DS-8201. Seattle Genetics said Daiichi’s filing circumvented the dispute-resolution process in their former agreement; both parties disputed the other’s claims to the technology.
Sources10 sources
- 1Seagenen.wikipedia.org
- 2Pfizer Completes Acquisition of Seagenpfizer.com
- 3Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagenpfizer.com
- 4Seagen | Pfizerpfizer.com
- 5Pfizer pulls plug on mammoth Seagen pharma factory in Everettseattletimes.com
- 6Pfizer announces acquisition agreementpfizer.com
- 7Daiichi Sankyo files declaratory judgment action against Seattle Geneticsfiercebiotech.com
- 8Pfizer 与 Seagen 获得收购所需监管批准finanznachrichten.de
- 9Pieris与Seagen修订合作并达成临床试验合作finanznachrichten.de
- 10Daiichi Sankyo sues Seattle Genetics over antibody-drug conjugate technology - MedCity Newsmedcitynews.com
Cite this profile: Cite the canonical profile. /brand-wiki/seagen · Editorial policy · How profiles are compiled